Skip to content

I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA Vasculitis

The Role of Intestinal Fatty Acid Binding Protein in Predicting Gastrointestinal Involvement in Pediatric IgA Vasculitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07664228
Acronym
IFABP-IgAV
Enrollment
100
Registered
2026-06-24
Start date
2026-05-15
Completion date
2027-05-15
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Involvement, IgA Vasculitis

Keywords

IgA Vasculitis, Henoch-Schönlein Purpura, I-FABP, Intestinal Fatty Acid Binding Protein, Gastrointestinal Involvement, Children, Pediatric Rheumatology

Brief summary

This prospective observational study aims to evaluate plasma intestinal fatty acid-binding protein (I-FABP) levels in children with IgA vasculitis and investigate their association with gastrointestinal involvement. Blood samples will be collected at diagnosis and during follow-up 2-4 weeks later. The study will assess the potential value of plasma I-FABP as a biomarker for gastrointestinal involvement in pediatric IgA vasculitis.

Detailed description

This prospective observational cohort study aims to evaluate the association between plasma intestinal fatty acid-binding protein (I-FABP) levels and gastrointestinal involvement in children with IgA vasculitis (Henoch-Schönlein purpura). Children aged 2-18 years who fulfill the EULAR/PRINTO/PRES classification criteria for IgA vasculitis will be enrolled. Clinical, laboratory, and demographic data will be collected at diagnosis (baseline). Participants will be followed prospectively, and a second assessment will be performed during the routine follow-up visit at approximately 2-4 weeks after diagnosis. Blood samples will be obtained at baseline and during follow-up. Plasma will be separated and stored for subsequent measurement of I-FABP levels. The primary objective is to determine whether plasma I-FABP levels are associated with the presence of gastrointestinal involvement in pediatric IgA vasculitis. Participants will be classified according to the presence or absence of gastrointestinal involvement. Clinical manifestations, laboratory findings, and plasma I-FABP levels will be compared between groups. The study does not involve administration of investigational drugs, devices, or therapeutic interventions. All procedures are performed as part of routine clinical follow-up with additional blood sampling for biomarker analysis. The findings may help identify noninvasive biomarkers for the early detection and assessment of gastrointestinal involvement in children with IgA vasculitis.

Interventions

DIAGNOSTIC_TESTPlasma I-FABP Measurement

Blood samples are collected and plasma I-FABP levels are measured to evaluate gastrointestinal involvement in pediatric IgA vasculitis.

Sponsors

Bursa City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of IgA vasculitis (Henoch-Schönlein purpura) according to EULAR/PRINTO/PRES classification criteria. * Age between 2 and 18 years. * Availability for blood sample collection at diagnosis (baseline visit). * Ability to attend a routine follow-up visit approximately 2-4 weeks after diagnosis. * Parent or legal guardian able and willing to provide written informed consent.

Exclusion criteria

* Refusal of informed consent by the parent/legal guardian. * Inability to obtain a baseline blood sample. * Inability to complete study follow-up procedures.

Design outcomes

Primary

MeasureTime frameDescription
Plasma I-FABP LevelsAt baseline (T0) and at follow-up 2-4 weeks after diagnosisAssessment of plasma I-FABP levels and their association with gastrointestinal involvement in pediatric IgA vasculitis patients.

Countries

Turkey (Türkiye)

Contacts

CONTACTNur Şeyma Zengin, MD
nszengin37@hotmail.com+90 5064767328
CONTACTTuba Kurt, MD, Associate Professor
drtubakurt@hotmail.com+90 553 064 1000
PRINCIPAL_INVESTIGATORTuba Kurt, MD, Associate Professor

Health Sciences University Bursa City Hospital, Department of Pediatric Rheumatology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026